Does PGEN pay a dividend?

The cached stock data on this page does not show a positive dividend yield for PGEN. Dividend status can change, so verify the latest company filings before relying on income assumptions.

What does PGEN stock do?

Precigen is a clinical-stage biopharmaceutical company leveraging gene and cell therapy platforms (UltraVector, Sleeping Beauty, AdenoVerse, UltraCAR-T). Revenue is currently non-commercial, driven primarily by licensing agreements, research grants, and legacy platform collaborations.

What is PGEN stock's price target?

This cached page does not contain a precise model fair value for PGEN.

The TradeMates model verdict for PGEN is AVOID with an investment score of 35/100. Treat this as a model signal to review, not a personal buy recommendation.

Is PGEN a good dividend stock?

PGEN is not presented as a dividend idea on this cached TradeMates page because no positive dividend yield is available in the cached data.

PGEN (PGEN) Stock Analysis

Q: Is PGEN stock a good investment?

The cached TradeMates AI model rates PGEN as AVOID with an investment score of 35/100. The AI model assesses PGEN as high-risk with an imminent capital raising requirement, overriding bullish analyst price targets. This is algorithmic model output, not personal investment advice.

Verdict: AVOID

PGEN trades near 52W highs on clinical expectations, but severe cash burn ($90M/yr) vs $30M cash signals imminent dilution risk.

Investment score: 35/100

The AI model assesses PGEN as high-risk with an imminent capital raising requirement, overriding bullish analyst price targets.

View the full interactive analysis